JP2015512393A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512393A5 JP2015512393A5 JP2015501792A JP2015501792A JP2015512393A5 JP 2015512393 A5 JP2015512393 A5 JP 2015512393A5 JP 2015501792 A JP2015501792 A JP 2015501792A JP 2015501792 A JP2015501792 A JP 2015501792A JP 2015512393 A5 JP2015512393 A5 JP 2015512393A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- hair growth
- antagonist
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003779 hair growth Effects 0.000 claims description 57
- 239000000203 mixture Substances 0.000 claims description 55
- 239000003795 chemical substances by application Substances 0.000 claims description 48
- 201000004384 Alopecia Diseases 0.000 claims description 30
- 239000005557 antagonist Substances 0.000 claims description 30
- 239000000556 agonist Substances 0.000 claims description 22
- 230000002401 inhibitory effect Effects 0.000 claims description 18
- 230000004936 stimulating effect Effects 0.000 claims description 18
- 206010068168 androgenetic alopecia Diseases 0.000 claims description 16
- 201000002996 androgenic alopecia Diseases 0.000 claims description 10
- 231100000360 alopecia Toxicity 0.000 claims description 8
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 8
- 230000003676 hair loss Effects 0.000 claims description 4
- 208000024963 hair loss Diseases 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 claims description 4
- 230000033228 biological regulation Effects 0.000 claims description 3
- 210000004209 hair Anatomy 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- VSRXYLYXIXYEST-KZTWKYQFSA-N 13,14-dihydro-15-ketoprostaglandin D2 Chemical compound CCCCCC(=O)CC[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O VSRXYLYXIXYEST-KZTWKYQFSA-N 0.000 claims description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims description 2
- LDXDSHIEDAPSSA-OAHLLOKOSA-N Ramatroban Chemical group N([C@@H]1CCC=2N(C3=CC=CC=C3C=2C1)CCC(=O)O)S(=O)(=O)C1=CC=C(F)C=C1 LDXDSHIEDAPSSA-OAHLLOKOSA-N 0.000 claims description 2
- 230000008485 antagonism Effects 0.000 claims description 2
- 208000034557 congenital alopecia Diseases 0.000 claims description 2
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims description 2
- 210000004207 dermis Anatomy 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 210000002615 epidermis Anatomy 0.000 claims description 2
- 229960004039 finasteride Drugs 0.000 claims description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 claims description 2
- 210000003780 hair follicle Anatomy 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 201000011486 lichen planus Diseases 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229960003632 minoxidil Drugs 0.000 claims description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical group OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims description 2
- 229950004496 ramatroban Drugs 0.000 claims description 2
- 230000037390 scarring Effects 0.000 claims description 2
- BOIZHGCLUSQNLD-UHFFFAOYSA-N acetic acid;1h-indole Chemical group CC(O)=O.C1=CC=C2NC=CC2=C1 BOIZHGCLUSQNLD-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 54
- 101710155962 Diuretic hormone 2 Proteins 0.000 description 52
- 230000000694 effects Effects 0.000 description 48
- 238000000034 method Methods 0.000 description 42
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 24
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 24
- 101710155964 Diuretic hormone 1 Proteins 0.000 description 21
- 238000012216 screening Methods 0.000 description 6
- 150000003180 prostaglandins Chemical class 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- QOPBEBWGSGFROG-UHFFFAOYSA-N 2-(1h-indol-2-yl)acetic acid Chemical group C1=CC=C2NC(CC(=O)O)=CC2=C1 QOPBEBWGSGFROG-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261613829P | 2012-03-21 | 2012-03-21 | |
| US61/613,829 | 2012-03-21 | ||
| PCT/US2013/031825 WO2013142295A1 (en) | 2012-03-21 | 2013-03-15 | Compositions and methods for regulating hair growth |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017155603A Division JP2017197585A (ja) | 2012-03-21 | 2017-08-10 | 発毛を調節するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015512393A JP2015512393A (ja) | 2015-04-27 |
| JP2015512393A5 true JP2015512393A5 (enExample) | 2016-05-12 |
| JP6193968B2 JP6193968B2 (ja) | 2017-09-06 |
Family
ID=49223241
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015501792A Active JP6193968B2 (ja) | 2012-03-21 | 2013-03-15 | 発毛を調節するための組成物および方法 |
| JP2017155603A Pending JP2017197585A (ja) | 2012-03-21 | 2017-08-10 | 発毛を調節するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017155603A Pending JP2017197585A (ja) | 2012-03-21 | 2017-08-10 | 発毛を調節するための組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2827952B1 (enExample) |
| JP (2) | JP6193968B2 (enExample) |
| KR (1) | KR102205774B1 (enExample) |
| CN (2) | CN108938441A (enExample) |
| AU (4) | AU2013235439B2 (enExample) |
| CA (1) | CA2867901A1 (enExample) |
| EA (1) | EA033143B1 (enExample) |
| ES (1) | ES2895660T3 (enExample) |
| IL (1) | IL234740A0 (enExample) |
| WO (1) | WO2013142295A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2037967T3 (en) | 2006-06-16 | 2017-03-13 | Univ Pennsylvania | PROSTAGLANDIN-D2 RECEPTOR ANTAGONISTS FOR TREATMENT OF ANDROGENETIC ALOPECI |
| EP3178465A1 (en) | 2010-12-06 | 2017-06-14 | Follica, Inc. | Methods for treating baldness and promoting hair growth |
| US11696883B2 (en) | 2014-05-23 | 2023-07-11 | Triple Hair Inc. | Compositions for reducing hair loss and/or increasing hair regrowth |
| WO2015176161A1 (en) * | 2014-05-23 | 2015-11-26 | Triple Hair Inc. | Compositions for reducing hair loss and/or increasing hair regrowth |
| CA2983942A1 (en) * | 2015-04-30 | 2016-11-03 | Allergan, Inc. | Cosmetic method and therapeutic use for fat reduction |
| PL3347009T3 (pl) | 2015-07-08 | 2022-02-07 | Triple Hair Inc. | Kompozycja zawierająca resweratrol i melatoninę ograniczająca wypadanie włosów i/lub zwiększająca odrastanie włosów |
| US12201625B2 (en) * | 2015-07-30 | 2025-01-21 | The Trustees Of The University Of Pennsylvania | Single nucleotide polymorphic alleles of human DP-2 gene for detection of susceptibility to hair growth inhibition by PGD2 |
| CN106214592B (zh) * | 2016-09-09 | 2019-03-15 | 美萃国际贸易（上海）有限公司 | 毛囊营养液组合物及其制备方法 |
| KR101857408B1 (ko) * | 2018-02-28 | 2018-05-14 | 경북대학교 산학협력단 | 탈모 예방 또는 치료용 조성물 |
| GB202005548D0 (en) * | 2020-04-16 | 2020-06-03 | Hairclone Ltd | Method of determining the androgen-sensitivity of a hair follicle |
| CN119841890A (zh) * | 2025-03-21 | 2025-04-18 | 杭州佰倍优生物科技有限公司 | 一种促进毛囊重建的血蛋白肽及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
| SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| WO2003097042A1 (en) | 2002-05-16 | 2003-11-27 | Shionogi & Co., Ltd. | Pgd2 receptor antagonist |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| EA011385B1 (ru) | 2002-10-04 | 2009-02-27 | Миллениум Фармасьютикалз, Инк. | Антагонисты рецептора pgd2 для лечения воспалительных заболеваний |
| WO2004035543A1 (en) | 2002-10-21 | 2004-04-29 | Warner-Lambert Company Llc | Tetrahydroquinoline derivatives as crth2 antagonists |
| EP1435356A1 (en) | 2003-01-06 | 2004-07-07 | Warner-Lambert Company LLC | Quinoline derivatives as CRTH2 antagonists |
| SE0301569D0 (sv) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
| SE0302232D0 (sv) * | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
| SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
| WO2005040112A1 (en) | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds with pgd2 antagonist activity |
| GB2407318A (en) | 2003-10-23 | 2005-04-27 | Oxagen Ltd | Substituted Indol-3-yl acetic acid derivatives |
| US20050112075A1 (en) * | 2003-11-25 | 2005-05-26 | Hwang Cheng S. | Reduction of hair growth |
| SE0303180D0 (sv) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| EP1882937B1 (en) * | 2005-05-17 | 2012-02-22 | Taiho Pharmaceutical Co., Ltd. | Method for diagnosis of severity and prediction of recurrence in eosinophilic inflammatory disease |
| DK2037967T3 (en) * | 2006-06-16 | 2017-03-13 | Univ Pennsylvania | PROSTAGLANDIN-D2 RECEPTOR ANTAGONISTS FOR TREATMENT OF ANDROGENETIC ALOPECI |
| AU2007279079A1 (en) * | 2006-07-22 | 2008-01-31 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| CN102802621A (zh) * | 2009-06-17 | 2012-11-28 | 阿德兰斯研究学院有限公司 | 用于增强真皮细胞的毛原性能力的方法和组合物 |
| KR20120046762A (ko) * | 2009-07-31 | 2012-05-10 | 판미라 파마슈티칼스, 엘엘씨 | Ｄｐ2 수용체 길항제의 피부 제형 |
| PH12012501349A1 (en) * | 2010-01-06 | 2013-01-14 | Panmira Pharmaceuticals Llc | Dp2 antagonist and uses thereof |
| EP2538963B8 (en) * | 2010-02-24 | 2017-08-02 | Advangen International Pty Ltd | Method of treatment or prevention of hair loss or for the enhancement of hair growth |
| US20100172865A1 (en) * | 2010-03-18 | 2010-07-08 | Shantha Totada R | Methods of enhancing hair growth |
| EP3178465A1 (en) * | 2010-12-06 | 2017-06-14 | Follica, Inc. | Methods for treating baldness and promoting hair growth |
-
2013
- 2013-03-15 CN CN201810834487.1A patent/CN108938441A/zh active Pending
- 2013-03-15 CA CA2867901A patent/CA2867901A1/en not_active Abandoned
- 2013-03-15 WO PCT/US2013/031825 patent/WO2013142295A1/en not_active Ceased
- 2013-03-15 ES ES13764527T patent/ES2895660T3/es active Active
- 2013-03-15 AU AU2013235439A patent/AU2013235439B2/en active Active
- 2013-03-15 KR KR1020147029335A patent/KR102205774B1/ko active Active
- 2013-03-15 EP EP13764527.1A patent/EP2827952B1/en active Active
- 2013-03-15 EA EA201491737A patent/EA033143B1/ru not_active IP Right Cessation
- 2013-03-15 CN CN201380026128.9A patent/CN104602763B/zh active Active
- 2013-03-15 JP JP2015501792A patent/JP6193968B2/ja active Active
-
2014
- 2014-09-18 IL IL234740A patent/IL234740A0/en unknown
-
2017
- 2017-08-10 JP JP2017155603A patent/JP2017197585A/ja active Pending
-
2018
- 2018-02-23 AU AU2018201331A patent/AU2018201331A1/en not_active Abandoned
-
2019
- 2019-06-28 AU AU2019204620A patent/AU2019204620A1/en not_active Abandoned
-
2021
- 2021-05-18 AU AU2021203172A patent/AU2021203172A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512393A5 (enExample) | ||
| MX2023000943A (es) | Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y metodos de uso de los mismos. | |
| MX2021011563A (es) | Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen. | |
| CA3016092C (en) | POLYCRYSTALLINE FORM OF FREE BASIC OR SALT EGFR INHIBITOR ACID, PROCESS FOR ITS PREPARATION AND APPLICATION | |
| WO2005091991A3 (en) | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders | |
| MX2011008910A (es) | Derivados de azol sustituidos, composicion farmaceutica que comprende los derivados, y uso de los derivados para tratar enfermeda de parkinson. | |
| WO2014091298A3 (en) | Nitrogen containing morphinan derivatives and the use thereof | |
| WO2012092628A3 (en) | Patches and methods for the transdermal delivery of agents to treat hair loss | |
| UA105794C2 (uk) | 1,3-ДИЗАМІЩЕНІ ПОХІДНІ ІМІДАЗОЛІДИН-2-ОНУ ЯК ІНГІБІТОРИ Cyp17 | |
| NZ590796A (en) | Film-forming liquid formulations for drug release to hair and scalp | |
| MD4489B1 (ro) | Derivaţi de 1,4-benzotiazepină, procedeu de sinteză a lor, compoziţii farmaceutice care le conţin şi utilizarea acestora pentru tratarea sau prevenirea afecţiunilor care implică modularea receptorilor de rianodină | |
| EP4520398A3 (en) | Treatment of prostate cancer | |
| MX2022013482A (es) | Compuestos utiles para inhibir la quinasa ret. | |
| RU2013125042A (ru) | Способ предотвращения или лечения опухоли кожи | |
| MY165003A (en) | Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative | |
| RU2020109376A (ru) | Применение антагонистов рецептора ep4 для лечения nash- ассоциированного рака печени | |
| MY163235A (en) | Pharmaceutical preparation containing pyridylaminoacetic acid compound | |
| NZ731850A (en) | System and method for preventing alopecia | |
| MX2024014626A (es) | Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton | |
| ZA202212095B (en) | Il4i1 inhibitors and methods of use | |
| MX2019010096A (es) | Derivados de 1, 4, 6-trisustituidos-2-alquil-1h-benzo[d]imidazol como inhibidores de dihidroorotato oxigenasa. | |
| EA201991355A1 (ru) | Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта | |
| WO2012112447A3 (en) | Histone deacetylase inhibitors and methods of use thereof | |
| MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. | |
| EA200970764A1 (ru) | Способ лечения расстройств, вызванных пролиферацией клеток, с применением стимуляторов секреции гормона роста |